The Latest Cardiac and Vascular News
SUNNYVALE, Calif., April 04, 2023 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the issuance of two patent grants related to enabling technologies for delivery of its investigational autologous and allogeneic cell therapies. The United States […]
Feasibility and safety demonstrated in patients with advanced heart failure Safe maximal dose for continuation into Phase 2 (Proof-of-Concept) identified Proof for successful heart remuscularization obtained Interim data on 15 patients with 800 million cells dose expected in Q2 2024 GÖTTINGEN, Germany, April 04, 2023 (GLOBE NEWSWIRE) — Repairon, a […]
— Approval of VAZKEPA® to Reduce the Risk of Cardiovascular (CV) Events in Adult Statin-Treated Patients at High CV Risk with Elevated Triglycerides and Other High-Risk Characteristics as Studied in REDUCE-IT –- — Heart Disease Second Leading Cause of Death in Men and Women Aged 45 and Older in Israel […]
CLEARWATER, Fla., April 3, 2023 /PRNewswire/ — Eleven years ago on Feb. 2, 2012, Morton Plant Hospital in Clearwater became the first hospital in the Tampa Bay area to replace a heart valve without open heart surgery. The structural heart team, led by Joshua Rovin, MD, FACS, cardiovascular surgeon and medical director of The Center for Advanced Valve and […]
SANTA CLARA, Calif., April 3, 2023 /PRNewswire/ — Semler Scientific, Inc. (Nasdaq: SMLR), a company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, commented on the recent Centers for Medicare and Medicaid Services (CMS) 2024 Medicare Advantage and Part D Final Rate Announcement. “Semler Scientific remains confident that screening […]
Ghent, Belgium – 03 April 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces that it has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) on 31 March 2023 for its second-generation […]
If subsequently approved, Entresto will be the first and only approved therapy for the treatment of symptomatic chronic heart failure patients aged 1 to <18 years in the European Union Pediatric heart failure is an important cause of childhood morbidity and mortality – up to a third of all pediatric […]
SHANGHAI, March 28, 2023 /PRNewswire/ — Pulnovo Medical Limited, a globally recognized OTM platform, announced the results from its PADN series study during the Late-Breaking Clinical Science (LBCS) session of the second Technology and Heart Failure Therapeutics (THT 2023), with the presentation of its follow-up findings from PADN-5 study. As the first […]
SAFE-MCS Examines the Impact of the Early Bird® Bleed Monitoring System on Reducing Bleeding Complications in Patients Undergoing High Risk PCI with Mechanical Circulatory Support HOUSTON–(BUSINESS WIRE)–Saranas, Inc. announced today that it has reached the midpoint for enrollment in SAFE-MCS, a multi-center, single arm, open-label clinical trial evaluating the safety […]
Oak Ridge, TN, March 27, 2023 (GLOBE NEWSWIRE) — Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announces five new hospitals have implemented the Company’s BVA-100 blood volume diagnostic for clinical use to guide fluid management in heart failure patients during the first quarter of 2023. The addition […]
